Gara Jalqabaatti › Luukemiya Limfoositiikii Keessummaa › Kansas
Qorannoo klinikaalii Luukemiya Limfoositiikii Keessummaa Kansas keessatti
Qorannoo 6 Luukemiya Limfoositiikii Keessummaa f Kansas keessatti hirmaatuu jiru.
Magaalota Kansas keessatti
Takkalaa qorannoo (Ingiliffa)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Cancer Center of Kansas - Chanute, Chanute
- Cancer Center of Kansas - Dodge City, Dodge City
- Cancer Center of Kansas - El Dorado, El Dorado
- fi 21 dabalataa
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 65 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Central Care Cancer Center - Garden City, Garden City
- Central Care Cancer Center - Great Bend, Great Bend
- Veteran Administration Eastern Kansas Healthcare, Leavenworth
- fi 4 dabalataa
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 40 hanga 75 · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT05334069Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- HaysMed, Hays
- University of Kansas Cancer Center, Kansas City
- Lawrence Memorial Hospital, Lawrence
- fi 5 dabalataa
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ful-2026 · NCT04269902A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- The University of Kansas Cancer Center, Westwood
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT06697184A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- The University of Kansas Cancer Center, Westwood
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT06973187A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- University of Kansas, Westwood
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 14-Sad-2025 · NCT05643742Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.